Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSITRON: Sofosbuvir + Ribavirin in IFN-intolerant/ineligible/unwilling Genotype 2/3 HCV
NCT01542788Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C (HCV) comparing SOF+RBV with Placebo (2 arms). Primary endpoints: Sustained Virologic Response at 12 Weeks Post-Treatment and Adverse Events Leading to Permanent Discontinuation of Study Drug. Started Mar 2012; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01542788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01542788.